Please wait while we open this resource.
K
Clinical reviews
EXTENDED LOW-DOSE APIXABAN AND SUPERFICIAL VEIN THROMBOSIS
Vanderbilt University Medical Center
PDF20263 pages201 KB
The research included 600 patients and focused on the primary outcome of first symptomatic SuVT over 12 months. Results indicated that low-intensity apixaban significantly reduced the risk of symptomatic SuVT compared to placebo. The study also examined secondary outcomes related to concomitant deep vein thrombosis (DVT) and pulmonary embolism (PE). The findings suggest potential therapeutic strategies targeting inflammatory pathways associated with superficial vein thrombosis.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology